drugset
drugset / Trial / NCT03758469

A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules

NCT03758469 ↗

Phase 1 Completed 16 enrolled Sichuan Haisco Pharmaceutical Group Co., Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

This is a Phase I, single-center, open-label, randomized,two-way crossover, propofol-controlled, two-stage study evaluating the safety and pharmacokinetics/pharmacodynamics of IV maintenance dose and IV single loade dose plus maintenance dose of HSK3486 emulsion for injection in healthy subjects.

Timeline

Start
2018-12-14
Primary completion
2019-01-31
Completion
2019-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cipepofol Small molecule 0.4 mg/kg Intravenous
Subject Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.